Topical nepafenac after intravitreal injection: a prospective double-masked
randomized controlled trial.
Author(s): Ulrich JN(1).
Affiliation(s): Author information:
(1)Department of Ophthalmology, University of North Carolina, Chapel Hill, North
Carolina.
Publication date & source: 2014, Retina. , 34(3):509-11
PURPOSE: To evaluate if a single drop of nepafenac can reduce the ocular
discomfort after intravitreal injections compared with placebo.
METHODS: One hundred and twenty patients undergoing intravitreal injections of
bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane
Ultra) after the injection in a prospective, double-masked, randomized controlled
design. Patients rated their pain levels from 0 to 3 (no pain, mild pain,
moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure.
RESULTS: Statistically significant reduction of postinjection pain with nepafenac
was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6
[standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1
± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15).
CONCLUSION: A single drop of nepafenac is effective in reducing discomfort after
intravitreal injections.
|